Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Vertex Pharmaceuticals Inc Stock Research

VRTX

349.53USD-4.75(-1.34%)Market Closed
Watchlist

Market Summary

USD349.53-4.75
Market Closed
-1.34%

VRTX Alerts

  • 4 major insider sales recently.

VRTX Stock Price

VRTX RSI Chart

VRTX Valuation

Market Cap

90.1B

Price/Earnings (Trailing)

26.78

Price/Sales (Trailing)

9.48

EV/EBITDA

18.12

Price/Free Cashflow

23.23

VRTX Price/Sales (Trailing)

VRTX Profitability

EBT Margin

45.28%

Return on Equity

22.59%

Return on Assets

17.18%

Free Cashflow Yield

4.3%

VRTX Fundamentals

VRTX Revenue

Revenue (TTM)

9.5B

Revenue Y/Y

13.52%

Revenue Q/Q

4.99%

VRTX Earnings

Earnings (TTM)

3.4B

Earnings Y/Y

12.98%

Earnings Q/Q

30.85%

Price Action

52 Week Range

276.57367.00
(Low)(High)

Last 7 days

0.2%

Last 30 days

-0.3%

Last 90 days

0.7%

Trailing 12 Months

22.1%

VRTX Financial Health

Current Ratio

4.28

VRTX Investor Care

Shares Dilution (1Y)

0.74%

Diluted EPS (TTM)

12.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for VRTX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-19
Bozic Carmen
sold
-1,983,500
351
-5,651
evp and cmo
2023-09-05
Bozic Carmen
sold
-1,992,880
352
-5,651
evp and cmo
2023-08-23
Tatsis Ourania
sold
-887,500
355
-2,500
evp, chief reg. & quality off.
2023-08-10
Kearney Terrence C
acquired
1,275,400
127
10,000
-
2023-08-10
Kearney Terrence C
sold
-3,500,000
350
-10,000
-
2023-08-10
Tatsis Ourania
sold
-1,988,290
345
-5,750
evp, chief reg. & quality off.
2023-08-10
Sachdev Amit
sold
-3,510,850
350
-10,031
evp, chief patient officer
2023-08-09
Bhatia Sangeeta N.
sold
-83,613
345
-242
-
2023-08-09
ALTSHULER DAVID
sold
-21,767
345
-63.00
evp, global research and cso
2023-07-17
SACHS BRUCE I
sold
-4,013,460
356
-11,250
-

1–10 of 50

Which funds bought or sold VRTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Baystate Wealth Management LLC
added
1.96
2,230
18,299
-%
2023-09-21
Jefferies Group LLC
added
29.66
104,486
418,964
-%
2023-09-20
BARCLAYS PLC
added
45.85
86,421,000
223,812,000
0.14%
2023-09-12
Farther Finance Advisors, LLC
added
5.84
7,862
51,027
0.01%
2023-09-12
Prosperity Wealth Management, Inc.
added
15.54
67,731
300,883
0.20%
2023-09-07
ST GERMAIN D J CO INC
new
-
26,393
26,393
-%
2023-09-07
JAG CAPITAL MANAGEMENT, LLC
reduced
-1.61
1,355,540
15,049,400
1.74%
2023-09-01
Portside Wealth Group, LLC
new
-
452,555
452,555
0.08%
2023-08-30
Western Wealth Management, LLC
new
-
340,297
340,297
0.03%
2023-08-28
DT Investment Partners, LLC
unchanged
-
42.00
5,217
-%

1–10 of 45

Latest Funds Activity

Are funds buying VRTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VRTX
No. of Funds

Schedule 13G FIlings of Vertex Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital world investors
5.0%
12,939,319
SC 13G
Feb 09, 2023
vanguard group inc
8.39%
21,546,903
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G
Jan 24, 2023
blackrock inc.
9.4%
24,241,437
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
2.1%
5,421,291
SC 13G/A
Feb 10, 2022
vanguard group inc
7.93%
20,155,842
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 01, 2022
blackrock inc.
9.4%
23,944,931
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
7.5%
19,626,208
SC 13G/A
Feb 10, 2021
vanguard group inc
7.86%
20,433,050
SC 13G/A

Recent SEC filings of Vertex Pharmaceuticals

View All Filings
Date Filed Form Type Document
Sep 21, 2023
4
Insider Trading
Sep 19, 2023
144
Notice of Insider Sale Intent
Sep 07, 2023
4
Insider Trading
Sep 05, 2023
144
Notice of Insider Sale Intent
Sep 05, 2023
3
Insider Trading
Aug 25, 2023
4
Insider Trading
Aug 23, 2023
144
Notice of Insider Sale Intent
Aug 14, 2023
4
Insider Trading
Aug 14, 2023
4
Insider Trading
Aug 14, 2023
4
Insider Trading

Peers (Alternatives to Vertex Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
269.9B
56.0B
3.85% 7.89%
31.08
4.82
-2.31% -31.27%
262.3B
1.8B
-6.03% 32.32%
-151.4
144.85
69.45% 14.65%
90.1B
9.5B
-0.31% 22.07%
26.78
9.48
13.83% 5.33%
88.3B
12.7B
-1.90% 19.84%
20.53
6.97
-10.94% -24.40%
21.4B
1.2B
-9.89% -15.37%
-20.15
17.32
39.94% -8.44%
11.2B
1.0B
4.78% 8.17%
-12.32
11.15
20.15% -79.16%
10.4B
2.1B
-3.76% 7.10%
11.99
4.95
18.01% 38.16%
MID-CAP
3.0B
225.6M
-0.48% -26.20%
-5.42
13.31
-2.11% 21.02%
2.8B
-
-14.43% 145.38%
-8.58
-
- -28.88%
2.6B
402.9M
-0.46% -15.55%
-3.61
6.46
20.50% -42.46%
2.4B
27.2M
9.19% -41.38%
-3.24
87.87
- -14.43%
SMALL-CAP
3.1B
-
-6.35% -39.96%
-7.31
33.28
34.30% -149.91%
1.3B
302.9M
-14.43% -0.82%
11.15
4.25
77.72% 112.02%
288.6M
152.5M
-11.24% 54.82%
38.75
1.89
127.84% 103.41%
30.1M
-
1.72% 3677.78%
-0.65
-
- -31.51%

Vertex Pharmaceuticals News

Investor's Business Daily
Dow Jones Futures Rise: Market Correction Smashing Leaders; Is ....
Investor's Business Daily,
2 hours ago
The Motley Fool
Investor's Business Daily
The Motley Fool
Investor's Business Daily
The Motley Fool

Returns for VRTX

Cumulative Returns on VRTX

16.7%


10-Year Cumulative Returns

21.3%


7-Year Cumulative Returns

14.2%


5-Year Cumulative Returns

9.3%


3-Year Cumulative Returns

Risks for VRTX

What is the probability of a big loss on VRTX?

25.8%


Probability that Vertex Pharmaceuticals stock will be more than 20% underwater in next one year

6.5%


Probability that Vertex Pharmaceuticals stock will be more than 30% underwater in next one year.

0%


Probability that Vertex Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VRTX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Vertex Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Financials for Vertex Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue3.2%9,5059,2088,9318,7018,3507,9487,5747,1306,6846,4156,2065,9915,4034,8194,1633,6203,4543,2653,0482,8292,623
Costs and Expenses7.3%5,5395,1634,6234,5494,2715,0124,7924,4794,4163,3913,3493,3293,3143,1792,9652,8462,5742,4822,4122,1962,521
  S&GA Expenses4.9%1,018971945933884863840797783780770754729694658616594575558539523
  R&D Expenses------3,1983,0512,8232,8231,8371,8301,8431,9051,8641,7551,7121,4871,4451,4161,2851,410
EBITDA-100.0%-4,2694,3264,1124,0122,9362,7952,8392,4993,3653,2012,9842,3071,8101,472------
EBITDA Margin-100.0%-0.46*0.48*0.47*0.48*0.37*0.37*0.40*0.37*0.52*0.52*0.50*0.43*0.38*0.35*------
Interest Expenses6.6%-47.90-51.30-54.80-58.30-59.80-60.70-61.50-30.11-28.77-27.14-25.57-27.611.0029.0059.0063.0067.0070.0072.00168136
Earnings Before Taxes3.3%4,3064,1694,2324,0273,9332,8642,7302,7482,4113,2803,1172,9052,2301,7321,395750816706600680127
EBT Margin-100.0%-0.45*0.47*0.46*0.47*0.36*0.36*0.39*0.36*0.51*0.50*0.48*0.41*0.36*0.34*------
Net Income3.2%3,3653,2603,3223,2733,1952,4512,3422,1761,9922,7622,7122,6912,0811,5111,1772,1442,2152,1552,097647415
Net Income Margin-100.0%-0.35*0.37*0.38*0.38*0.31*0.31*0.31*0.30*0.43*0.44*0.45*0.39*0.31*0.28*------
Free Cashflow-100.0%-3,8903,9253,8143,7872,4512,4091,9191,7773,0482,9942,9792,5571,9831,494------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets7.2%20,34918,97418,15116,70615,58214,25613,43312,61912,22212,11511,75211,30210,2168,8938,3187,5157,0336,5436,2624,6214,335
  Current Assets7.0%13,87312,96613,23512,27111,50410,3619,5618,8538,4588,5398,1337,4586,6945,4464,8234,7774,7114,1833,8433,6873,407
    Cash Equivalents9.3%10,1519,29010,5049,1728,7027,6006,7956,2766,0646,3045,9885,3584,8313,5933,1093,3983,2952,8942,6502,4782,145
  Inventory12.8%604535461388368339353333322299281245219187168162143137124124115
  Net PPE------------92172873674517.00731743812808816
  Goodwill0%1,0881,0881,08886.001,0021,0021,0021,0021,0021,0021,0001,0021,0021,0021,00244850.0050.0050.0050.0050.00
Liabilities7.4%4,8794,5424,2383,6773,6493,3493,3333,0883,0253,1353,0653,1682,6972,4322,2332,2611,9641,8201,8111,6861,621
  Current Liabilities10.8%3,3523,0262,7422,6092,5562,1802,1421,9141,8361,9441,8782,0041,7991,5391,3351,3891,2591,1061,120993927
Shareholder's Equity7.2%15,47014,43213,91313,03011,93410,90710,1009,5319,1968,9808,6878,1337,5196,4626,0855,2535,0704,7234,4352,9342,715
  Retained Earnings12.7%8,1387,2236,5235,7044,7733,9633,2012,4311,5791,512859254-412-1,250-1,852-2,436-2,493-2,761-2,989-4,540-4,668
  Additional Paid-In Capital2.1%7,3697,2207,3877,2267,1006,9306,8817,0867,6407,4997,8947,9177,9447,6967,9387,6687,5647,4767,4217,4437,357
Shares Outstanding0.1%258258257257256255254258259259260260260260259257256256255255254
Minority Interest--------------------28.0029.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-0.1%4,0684,0744,1304,0474,0182,6792,6442,1402,1213,3593,2543,2082,6352,0601,5691,4381,4841,3421,2701,183972
  Share Based Compensation1.1%489483491498466457441420416429430424410382361348348341325322311
Cashflow From Investing-11.5%-2,346-2,103-321-630-299-317-34037.00-158-6.5799.00-1,041-1,042-1,164-1,235-379-180-246-202-182-357
Cashflow From Financing-11.4%-297-267-67.70-444-1,040-1,054-1,478-1,267-750-664-505-218-57.60-190127-135-153-192-71.22103254
  Buy Backs19.2%158133-3681,0101,0101,4251,198664664539444348400186301381437350210118

VRTX Income Statement

2023-06-30
Condensed Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Product revenues, net$ 2,493.2$ 2,196.2$ 4,868.0$ 4,293.7
Costs and expenses:    
Cost of sales308.6261.8575.5507.6
Research and development expenses785.7600.11,528.31,201.2
Acquired in-process research and development expenses110.561.9457.663.9
Selling, general and administrative expenses262.6215.3503.7430.5
Change in fair value of contingent consideration(0.6)(49.2)(2.5)(56.7)
Total costs and expenses1,466.81,089.93,062.62,146.5
Income from operations1,026.41,106.31,805.42,147.2
Interest income144.710.8267.312.4
Interest expense(11.2)(14.6)(22.6)(29.5)
Other income (expense), net1.6(78.1)2.9(150.9)
Income before provision for income taxes1,161.51,024.42,053.01,979.2
Provision for income taxes245.8213.9437.5406.6
Net income$ 915.7$ 810.5$ 1,615.5$ 1,572.6
Net income per common share:    
Basic (in dollars per share)$ 3.55$ 3.17$ 6.27$ 6.15
Diluted (in dollars per share)$ 3.52$ 3.13$ 6.21$ 6.09
Shares used in per share calculations:    
Basic (in shares)257.7255.9257.6255.5
Diluted (in shares)260.4258.7260.3258.3

VRTX Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 10,151.1$ 10,504.0
Marketable securities1,085.2274.5
Accounts receivable, net1,556.21,442.2
Inventories603.5460.6
Prepaid expenses and other current assets476.9553.5
Total current assets13,872.913,234.8
Property and equipment, net1,122.41,108.4
Goodwill1,088.01,088.0
Intangible assets603.6603.6
Deferred tax assets1,538.01,246.9
Operating lease assets324.3347.4
Long-term marketable securities1,357.3112.2
Other assets442.7409.6
Total assets20,349.218,150.9
Current liabilities:  
Accounts payable363.0303.9
Accrued expenses2,598.12,126.7
Other current liabilities391.0311.5
Total current liabilities3,352.12,742.1
Long-term finance lease liabilities404.1430.8
Long-term operating lease liabilities363.5379.5
Other long-term liabilities759.3685.8
Total liabilities4,879.04,238.2
Commitments and contingencies0.00.0
Shareholders’ equity:  
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding0.00.0
Common stock, $0.01 par value; 500,000,000 shares authorized, 257,792,648 and 257,011,628 shares issued and outstanding, respectively2.62.6
Additional paid-in capital7,369.17,386.5
Accumulated other comprehensive (loss) income(39.8)0.8
Retained earnings8,138.36,522.8
Total shareholders’ equity15,470.213,912.7
Total liabilities and shareholders’ equity$ 20,349.2$ 18,150.9
Reshma Kewalramani
3900
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.